While all the Benign Prostatic Hyperplasia (BPH, n = 3) and non-aggressive prostate cancer (n = 4) showed positive CCND2 staining, only 50% of aggressive prostate cancer (n = 5) appeared to be positive with CCND2 expression (see Methods), consistent with one previous study53 showed that CCND2 proteins were frequently lost in a cohort of prostate cancer specimens by immunohistochemistry staining analysis. Here, CCND2 is linked to prostate cancer.